Cargando…

Radionuclides in the management of thyroid cancer

Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medici...

Descripción completa

Detalles Bibliográficos
Autor principal: Buscombe, J.R.
Formato: Texto
Lenguaje:English
Publicado: e-Med 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151327/
https://www.ncbi.nlm.nih.gov/pubmed/18083649
http://dx.doi.org/10.1102/1470-7330.2007.0029
_version_ 1782144722587877376
author Buscombe, J.R.
author_facet Buscombe, J.R.
author_sort Buscombe, J.R.
collection PubMed
description Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medicine techniques. It remains, however, one of the most dynamic areas of development in nuclear medicine with new roles for positron emission tomography and receptor based imaging. In addition to this is research into combinations of genetic therapy and radioisotopes and receptor based therapy using beta emitting analogues of somatostatin. Despite the use of ultrasound computed tomography and magnetic resonance, nuclear medicine techniques remain central to both imaging and therapy in thyroid disease and the field has recently become one of the most dynamic within the specialty.
format Text
id pubmed-2151327
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher e-Med
record_format MEDLINE/PubMed
spelling pubmed-21513272009-12-17 Radionuclides in the management of thyroid cancer Buscombe, J.R. Cancer Imaging Article Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medicine techniques. It remains, however, one of the most dynamic areas of development in nuclear medicine with new roles for positron emission tomography and receptor based imaging. In addition to this is research into combinations of genetic therapy and radioisotopes and receptor based therapy using beta emitting analogues of somatostatin. Despite the use of ultrasound computed tomography and magnetic resonance, nuclear medicine techniques remain central to both imaging and therapy in thyroid disease and the field has recently become one of the most dynamic within the specialty. e-Med 2007-12-17 /pmc/articles/PMC2151327/ /pubmed/18083649 http://dx.doi.org/10.1102/1470-7330.2007.0029 Text en © 2007 International Cancer Imaging Society
spellingShingle Article
Buscombe, J.R.
Radionuclides in the management of thyroid cancer
title Radionuclides in the management of thyroid cancer
title_full Radionuclides in the management of thyroid cancer
title_fullStr Radionuclides in the management of thyroid cancer
title_full_unstemmed Radionuclides in the management of thyroid cancer
title_short Radionuclides in the management of thyroid cancer
title_sort radionuclides in the management of thyroid cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151327/
https://www.ncbi.nlm.nih.gov/pubmed/18083649
http://dx.doi.org/10.1102/1470-7330.2007.0029
work_keys_str_mv AT buscombejr radionuclidesinthemanagementofthyroidcancer